The MONARCH 3 trial led to abemaciclib plus nonsteroidal aromatase inhibitor approval as initial therapy in postmenopausal patients with hormone receptor-positive (HR+), and human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer with significant improvement in progression-free survival. Prof. Matthew Goetz (Mayo Clinic, Rochester, MN, USA) joins touchONCOLOGY to discuss what the MONARCH 3 study teach us about the efficacy and safety of abemaciclib plus NSAI in patients with HR+, HER2- advanced breast cancer, the clinical impacts of the availability of abemaciclib, and the results of the interim overall survival analysis.
The abstract entitled ‘MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC)‘ Abstract LBA5, was presented at European Society for Medical Oncology (ESMO) 2022.
- What did the MONARCH 3 study teach us about the efficacy and safety of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients with HR+, HER2- advanced breast cancer (ABC)? (0:13)
- What has been the clinical impact of the availability of abemaciclib? (1:27)
- What were the results of the interim overall survival analysis? (2:27)
- Why do you think these findings failed to achieve statistical significance? (3:31)
- What further study is needed to optimise the clinical use of abemaciclib in ABC? (3:59)
Disclosures: Matthew P. Goetz serves as a paid consultant and receives grants for research funding paid to his institution from Eli Lilly and Company in support of the MONARCH 3 trial; reports personal fees from Genomic Health; consulting fees to his institution from AstraZeneca, Biovica, Pfizer, Novartis, Sermonix, Context Pharm, Eagle Pharmaceuticals; grants to his institution from Pfizer, Sermonix; honoraria to his institution for serving on the advisory board for ARC Therapeutics, Blueprint Medicines, Biotheranostics, and Sanofi Genzyme; personal fees from Research to Practice, Clinical Education Alliance, Medscape, MJH Life Sciences for CME presentations; and personal fees from Total Health Conferencing serving as a panelist, outside the submitted work.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.
Share this Video
Related Videos In Breast Cancer
Angela DeMichele, ASCO 2023: The PALLAS trial, palbociclib with adjuvant endocrine therapy in patients with stage II-III breast cancer
The PALLAS trial assessed the efficacy of adding palbociclib to adjuvant endocrine therapy in patients with stage II-III breast cancer. In this touchONCOLOGY interview, we speak with Dr Angela DeMichele (Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA) to discuss the PALLAS trial and how it compares to the other CDK4/6 inhibitor adjuvant trials, […]
Sara Tolaney, ASCO 2023: Highlights from the NATALEE trial of ribociclib and endocrine therapy in the treatment of breast cancer
touchONCOLOGY spoke with editorial board member Sara Tolaney (Dana-Farber Cancer Institute, Boston, MA, USA) to discuss her highlights from the ASCO annual meeting. She highlights data from the NATALEE study (NCT03701334), which met its primary endpoint at interim analysis, thus showing clinically meaningful benefit for patients with early breast cancer. The abstract entitled ‘Ribociclib and […]
Sara Tolaney, ASCO 2023: Primary outcome analysis of the phase 3 SONIA trial and the final overall survival results from the phase 3 TROPiCS-02 study
touchONCOLOGY spoke with editorial board member Sara Tolaney (Dana-Farber Cancer Institute, Boston, MA, USA) to discuss her highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting, 2–6, June 2023. These include the phase 3 SONIA trial (NCT03425838) assessing CDK4/6 inhibitors for patients with HR+, HER2- advanced breast cancer, and the final overall survival […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!